Alpha 2C Adrenergic Receptor Market

Global Alpha 2C Adrenergic Receptor Market Size, Share and Trend Analysis Report, By Type (Lacripep, JNJ-4789, SKL-PSY, and Other), By Application (Bipolar Disorder, Dry Eye, Major Depressive Disorder and Others), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2025894 | Category : Pharmaceuticals | Delivery Format: /

The global alpha 2C adrenergic receptor market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The alpha 2C adrenergic receptor is a G protein-coupled receptor (GPCR). It is associated with the Gi heterotrimeric G-protein. The major factor accelerating the growth of the market is the increasing prevalence of bipolar disorder across the globe.

According to the National Institute of Mental Health (NIMH), bipolar disorder affects approximately 5.7 million adults or about 2.6% of the population age 18 and older every year in the US. Additionally, the median age for bipolar disorder is 25 years, however, the illness can also start in early childhood or as late as 40-50 years of age. Further, as per the World Health Organization (WHO), epilepsy is one of the most common neurological diseases globally with around 50 million people diagnosed with it. Hence, the rising prevalence of bipolar disorder is increasing the demand for alpha 2C adrenergic receptors.

Some major players in the market include Johnson & Johnson Services, Inc., and Otsuka Holdings Co Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2021, Otsuka Pharmaceutical Co., Ltd. announced the regulatory approval of REXULTI (brexpiprazole), an orally disintegrating dose (OD) tablet in Japan. Brexpiprazole is a serotonin-dopamine activity modulator (SDAM). It acts as a partial agonist at 5-HT1A and dopamine D2 receptors and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type

o By Application

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- Johnson & Johnson Services, Inc., and Otsuka Holdings Co Ltd., among others. 

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Alpha 2C Adrenergic Receptor Market Report by Segment

By Type 

    • Lacripep

    • JNJ-4789

    • SKL-PSY

    • Others

By Application

    • Bipolar Disorder

    • Dry Eye

    • Major Depressive Disorder

    • Others

Global Alpha 2C Adrenergic Receptor Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa